Stock Analysis: Ionis Pharmaceuticals (IONS)
Notes: Stock Ratings: 1 = buy at current stock prices, 2 = buy on a 5-10% dip in stock price, 3 = sell on a 5-10% increase in stock price, 4 = sell at current stock prices to raise cash. Ratings are based upon 12-18 month outlook on stock direction and not necessarily related to moves I make due to financial positioning. Yesterday, we heard a slew of news come from Ionis Pharmaceuticals, so I thought it might be worth taking a moment to look at the information and determine if it has an effect on the stock's performance or my thesis. There were 3 major press events today. First, this morning they announced the results from their COMPASS phase 3 study for Volanesorsen. Then after the closing bell they announced the advancement into the pre-clinical phase of an unnamed cardiovascular disease treatment. Finally, CEO Stanley Crooke appeared on CNBC's "Mad Money" to talk about his company and their announcements. First up is the Volanesorsen de...